We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls ...

Sana Biotechnology's favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a ...

Actor Gene Hackman's longtime New Mexico compound has hit the market for $6.25 million, one year after he and his wife, Betsy ...

On Thursday, Deepwater Asset Management's managing partner Gene Munster said new signals from Nvidia Corp (NASDAQ:NVDA) and ...

Ocugen also reported updated results from a phase 1 trial, which showed that ellipsoid zone (EZ) loss – which results in the ...

British animal genetics company Genus expects to report full-year adjusted pretax profit "moderately above" the upper end of current market expectations, sending its shares as much as 15.3% higher on ...

Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...

The 35th annual Stock & Land Beef Week, hosted by Stud Beef Victoria, is shaping up to be one of the best.

Cathie Wood’s Ark Invest began the new year with a focus on innovation themes like autonomy, gene editing, and advanced air ...

Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited ...

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed ...

Finbold decided to examine potentially undervalued stocks that could help investors turn relatively modest investments into ...